Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MG-ZG122
- Development stage
- Phase 2
- Lead developer
- Shanghai Maiji Biotechnology
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous
01
Overview
MG-ZG122 is a humanized monoclonal antibody developed by Shanghai Mabgeek Biotech (also referred to as Hunan Mabgeek Biotech or Shanghai Maiji Biotechnology) for the treatment of immune system and respiratory diseases, including asthma, chronic obstructive pulmonary disease (COPD), and atopic dermatitis. It is being investigated as a potential therapy for non-Th2 asthma patients and is expected to offer an alternative to existing anti-asthma biologics such as anti-IgE and anti-IL-5 pathway antibodies. The drug acts as an **immunomodulator**; however, its precise molecular target has not been disclosed publicly. MG-ZG122 is administered via subcutaneous injection and is currently in Phase 1 clinical trials in China[1][2][3][4][5].
- Other names
- mg-zg122 humanized monoclonal antibody injectionmg-zg-122 humanized monoclonal antibody injectionmg-zg 122 humanized monoclonal antibody injectionmgzg 122mgzg122mgzg-122
Beyond the preview
Go deeper on MG-ZG122.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MG-ZG122.